Methods of use for car t cells

A method of treatment of a cancer in a human patient, wherein the human patient's bloodstream comprises a CAR T cell composition and one or more cancer cells, wherein the CAR T cell composition comprises CAR T cells that specifically bind to a targeting moiety and the one or more cancer cells specifically bind to a small molecule ligand;

• the method comprising administering to a human patient a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises the small molecule ligand linked to the targeting moiety by a linker, wherein:
• the small molecule ligand is folate, and the targeting moiety is a fluorescein, fluorescein isothiocyanate (FITC), or NHS-fluorescein;
• the compound, or the pharmaceutically acceptable salt thereof, is administered continuously to the human patient for at least one hour, at least 4 hours, at least six hours, or is administered three times weekly;
• and
• the compound specifically binds to both the CAR T cells and to the one or more cancer cells, thereby treating the human patient for the cancer.